Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
194.11
-0.27 (-0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
Where Biogen Stands With Analysts
April 11, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 09, 2024
Via
Benzinga
Looking Into Biogen's Recent Short Interest
April 03, 2024
Via
Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
March 29, 2024
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...
Via
Talk Markets
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Forecasting The Future: 18 Analyst Projections For Biogen
March 25, 2024
Via
Benzinga
A Closer Look at 21 Analyst Recommendations For Biogen
March 05, 2024
Via
Benzinga
Biogen Unusual Options Activity
February 29, 2024
Via
Benzinga
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
Via
Talk Markets
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
March 20, 2024
Via
Benzinga
Peering Into Biogen's Recent Short Interest
February 19, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
March 16, 2024
Over the past twelve months a number of big named companies have been near or below their 52 week low price. Each week we’ll take a look at some of the biggest names currently close to their 52 week...
Via
Talk Markets
Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
March 08, 2024
February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
March 08, 2024
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA...
Via
Benzinga
Exposures
Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
March 08, 2024
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab.
Via
Investor's Business Daily
Exposures
Product Safety
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
March 02, 2024
Getting its Alzheimer's medicine approved in the European Union could be big.
Via
The Motley Fool
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.
Via
InvestorPlace
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
February 14, 2024
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.
Via
Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
February 14, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
February 13, 2024
BIIB earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
February 13, 2024
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.